Clinical Evidence for Hepaxa™ and Hepaxa™PD

The reduction of liver fat (in people with NAFLD) has a powerful effect on T2D, glycemic control and hypertension. 5

“Steatosis is now considered the initial step in a pathway that leads to advanced liver disease…” 2

A partial and temporary reduction in steatosis is associated with improved health outcomes (T2D) over a 10 year period. 4

Multiple studies utilizing PUFA for dietary management of NAFLD

In an RCT, DHA supplementation decreases liver fat and visceral fat, and ameliorates metabolic abnormalities in children with NAFLD. A

In an RCT, DHA supplementation improves liver steatosis in children with NAFLD. B

In an RCT, DHA supplementation in children decreased the rate of steatosis, elevated ALT and elevated AST in the 12-month treatement in the PUFA group. C

Multiple studies utilizing PUFA for dietary management of Pediatric NAFLD

References:
1) V. Nobili, et. Al; Nutrition, Metabolism & Cardiovascular Diseases (2013) 23, 1066e1070
2) McPherson, S., et.Al, Journal of Hepatology 2015 vol. 62 j 1148–1155
3) L. Pacifico, et. Al; Nutrition, Metabolism & Cardiovascular Diseases (2015) 25, 734e741
4) Yamazaki, H., et.Al, Diabetes Care 2015;38:1673–1679
5) Peters et al, Journal of Nutritional Science, 2017, vol. 6, e15
6) Boyraz, M et. Al, J Clin res Endocrinol, 2015; 7(2): 121-27

Hepaxa™ – Turning NAFLD around.